All In Biotech

NDA 209401 · Jazz Pharms Therap

Vyxeos

Cytarabine, Daunorubicin · Intravenous · Nucleoside Metabolic Inhibitor; Anthracycline Topoisomerase Inhibitor

Breakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jan 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Aug 3, 2017

Approved uses

4

Original approval plus efficacy supplements

Registered trials

1,688

354 Phase 3, 228 recruiting

FAERS reports

2,431

2,136 serious, 825 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS • VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors [see Warnings and Precautions ( 5.1 )] . WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS See full prescribing information for complete boxed warning. • VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors ( 5.1 ).

What it is approved for

From the label in effect Jan 30, 2026.

VYXEOS is indicated for the treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor, that is indicated for the treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. ( 1 )

Mechanism: VYXEOS (daunorubicin and cytarabine) liposome for injection is a liposomal formulation of daunorubicin and cytarabine at a fixed 1:5 molar ratio. The 1:5 molar ratio of daunorubicin:cytarabine has been shown to have synergistic effects at killing leukemia cells in vitro and in murine models. Daunorubicin has antimitotic and cytotoxic activity, which is achieved by forming complexes with DNA, inhibiting topoisomerase II activity, inhibiting DNA polymerase activity, affecting regulation of gene expression, and producing DNA-damaging free radicals. Cytarabine is a cell cycle phase-specific...

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 27, 2026 Supplement 18 · Efficacy · priority review OrphanLetterLabel
  • Sep 27, 2022 Supplement 11 · Efficacy OrphanLetterLabel
  • Mar 30, 2021 Supplement 6 · Efficacy · priority review OrphanLabelLetter
  • Aug 3, 2017 Original approval · Type 4 - New Combination · priority review Breakthrough therapyOrphanLabelLetterReview
1 products under this application
  • VYXEOS · CYTARABINE 100MG; DAUNORUBICIN 44MG · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cytarabine" as an intervention, any sponsor and status, largest first.

All 1,688 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia528
  • acute myeloid leukaemia313
  • death244
  • therapeutic product effect incomplete217
  • pyrexia206
  • acute myeloid leukaemia recurrent177
  • rash152
  • pneumonia151
  • sepsis142
  • off label use121
  • cytopenia81
  • disease progression80

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201712
201877
2019231
2020183
2021171
2022346
202374
2024471
2025455
2026411

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Vyxeos (Daunorubicin/Cytarabine Lipos) · HCPCS J9153

2024 spending

$5.5M

Beneficiaries

101

245 claims

Per beneficiary

$54,468

2024 ASP limit $237.17 per unit

View as table
YearSpending
2020$8,651,250
2021$5,444,633
2022$6,925,015
2023$4,831,182
2024$5,501,271

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,783 on PubMed

Sponsor: Jazz Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.